Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Vasograin Plus represents a major advancement in the treatment of migraine
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
Subscribe To Our Newsletter & Stay Updated